Previous 10 | Next 10 |
2023-03-29 09:06:20 ET CV Sciences press release ( OTCQB:CVSI ): FY Non-GAAP EPS of -$0.05. Revenue of $16.2M (-19.2% Y/Y). Cash balance of $0.6 million at year end compared to $1.4 million at the end of 2021; Recognized gross margin of 34.2% for fiscal year 2022 compa...
CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results PR Newswire SAN DIEGO , March 29, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp...
CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2022 RESULTS ON MARCH 29, 2023 PR Newswire SAN DIEGO , March 24, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness ...
2023-03-23 11:39:32 ET With a market size of 20 billion, there is plenty of long-term value for smoking %CessationProducts . And this company just received patent approval in another country for its smoking cessation product. Consumer wellness company %CVSciences (OTCQB: $CVSI) ...
CV Sciences Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol (CBD) and Nicotine for Treating Smokeless Tobacco Addiction PR Newswire The Company is seeking strategic opportunities to advance the development of this prog...
CV Sciences, Inc. Launches New Line of THC-Free Gummies and Softgels PR Newswire +PlusCBD™Daily Balance THC-Free products provide benefits of CBD without effects of THC SAN DIEGO , March 21, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVS...
CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD™ Reserve Collection Softgels PR Newswire Smaller bottle allows for consumers flexibility at a more affordable price SAN DIEGO , Jan. 18, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: ...
CV Sciences, Inc. (CVSI) Q3 2022 Earnings Conference Call November 14, 2022, 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference Call Participants Presentation Greetings, and welcome to th...
CV Sciences press release ( OTCQB:CVSI ): Q3 Non-GAAP EPS of -$0.01. Revenue of $3.75M (-26.6% Y/Y). Gross margin of 41.6% for third quarter of 2022, compared to 46.2% for the third quarter of 2021. Total cash balance of $1.1M at quarter end, compared to $1.4M at year ...
CV Sciences, Inc. Reports Third Quarter 2022 Financial Results PR Newswire SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing i...
News, Short Squeeze, Breakout and More Instantly...
CV Sciences, Inc. Reports First Quarter 2024 Financial Results PR Newswire SAN DIEGO , May 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS, A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER PR Newswire SAN DIEGO , May 13, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer we...
CV Sciences, Inc. To Announce First Quarter 2024 Results On May 14, 2024 PR Newswire SAN DIEGO , May 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company special...